Bifidobacterium Animalis Subsp. Lactis XLTG11 for Reduced Allergy Risk in Infants

This study focuses on the effects of a specific probiotic, Bifidobacterium Animalis Subsp. Lactis XLTG11, on the growth, development, and immune function of infants. The research aims to understand how this probiotic might reduce the risk of allergies in healthy infants and young children under 3 years old. The study is important because early childhood is a critical time for the development of the gut microbiome and immune system. Imbalances during this period can lead to allergies, respiratory issues, and gastrointestinal disorders, which are common health problems in children worldwide. During the 180-day trial, participants receive either the probiotic or a placebo daily. The study measures the benefits of the probiotic across various health areas, including allergies, respiratory, and gastrointestinal symptoms. It also evaluates safety outcomes such as growth parameters and bowel habits. To understand how the probiotic works, the study uses advanced techniques like shotgun metagenomic sequencing to analyze changes in gut bacteria. It also measures certain immune markers to see how the probiotic might strengthen the body's natural defenses. The main goal is to determine if the probiotic can reduce allergy symptoms in children, as assessed through a hospital-based clinical questionnaire.